My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

95.47 -2.35 (-2.41%)
Streaming Delayed Price Updated: 12:27 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 Next >
Tilray Brands Posts Upbeat Results, Joins Byrna Technologies, Delta Air Lines And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
AMD To Rally More Than 47%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Why Is Abivax Stock Trading Higher On Monday?
Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no new safety concerns. 
Via Benzinga
Earnings Outlook For Abivax
 
Via Benzinga
Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease
The company is working on a treatment for a form of inflammatory bowel disease, a highly watched disease area. 
Via Investor's Business Daily
Topics Government
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
From Abivax
Via GlobeNewswire
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
From Abivax
Via GlobeNewswire
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
From Abivax
Via GlobeNewswire
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
From Abivax
Via GlobeNewswire
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
From Abivax
Via GlobeNewswire
RH Posts Downbeat Results, Joins Frequency Electronics, Tronox And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Abivax Presents First Half 2025 Financial Results
From Abivax
Via GlobeNewswire
Market Movers: Robinhood, AppLovin Surge into S&P 500 Amidst Crucial Earnings Season
The financial markets are abuzz with significant corporate developments as several key companies navigate pivotal moments, ranging from prestigious S&P index inclusions to critical quarterly earnings... 
Via MarketMinute
Topics Artificial Intelligence ETFs Retirement
This Stock Is Up by 800% This Year -- but Is It a Buy?
This little-known biotech might still deliver strong returns. 
Via The Motley Fool
Earnings Scheduled For August 11, 2025
 
Via Benzinga
Abivax Announces Closing of $747.5 Million Public Offering
From Abivax
Via GlobeNewswire
Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
From Abivax
Via GlobeNewswire
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
Abivax announces trading resumption of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
Abivax Announces Launch of Public Offering
From Abivax
Via GlobeNewswire
Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Dow Surges Over 200 Points; AT&T Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Abivax shares jump as obefazimod meets key Phase 3 trial endpoints in ulcerative colitis with strong remission rates and a favorable safety profile. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.